Evaluation Of Proton Pump Inhibitor Use Of Patients Enrolled In Family Health Centers In Terms Of Rational Drug Use
DOI:
https://doi.org/10.5281/zenodo.15988243Keywords:
Proton pump inhibitors, drug misuse, primary health care, drug prescriptions, education of patientsAbstract
Aim
Proton Pump Inhibitors (PPIs) have become mainstay medications for acid-related gastrointestinal diseases like Gastro-Esophageal Reflux Disease (GERD) and peptic ulcer disease. However, emerging data indicates potential adverse effects with long-term PPI use, including infections, fractures, kidney injury, vitamin deficiencies, and dementia. The aim of this study is to evaluate the prevalence, inappropriate use frequency, medication behaviors, and knowledge levels of PPI usage among patients presenting to family health centers in XXX, Turkey.
Materials and methods
This cross-sectional and prospective study was conducted over a 3-month period between 01.12.2022 and 01.03.2023. The data were collected with a questionnaire filled by face-to-face interviews.
Results
The study included 826 participants with a mean age of 44.5±14.9 years. The PPI prescription rate was 60.8%, with 42.4% (n=213) having used PPIs in the past 8 weeks. The most common reason for use was concurrent medication effects (31.6%), heartburn (29.5%), and stomach pain (15.0%). Most (74.5%, n=615) had no Gastro-Intestinal (GI) complaints, and among those with complaints the median duration was 6 months (range 1-240 months).
Conclusion
The findings highlight the need for continued research and awareness efforts to curb the irrational use of these important medications, an emerging global public health crisis. Implementation of clinical practice guidelines can help optimize utilization, improve patient outcomes, and prevent serious side effects and drug interactions due to excessive use.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 International Journal of Current Medical and Biological Sciences

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.